Monday, May 25, 2015

Sun Pharma settles Novartis lawsuit over leukemia drug

Sun Pharma's subsidiary holds a tentative approval from FDA for a generic version of Gleevec.

Sun Pharma is allowed to launch a generic version of Novartis' Gleevec in the US in 2016, under a settlement agreement between the two cos. (Reuters) Sun Pharma is allowed to launch a generic version of Novartis' Gleevec in the US in 2016, under a settlement agreement between the two cos. (Reuters)
By: Reuters | Mumbai | Published on:May 15, 2014 10:00 am

Sun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis’ leukemia drug Gleevec in the United States on Feb. 1, 2016, under a settlement agreement between the two companies.

The other terms of the agreement are confidential, Sun Pharma said in a statement on Thursday.

Sun Pharma’s subsidiary holds a tentative approval from the U.S Food and Drug Administration for a generic version of Gleevec. As per IMS data, Gleevec had annual sales of about $2 billion in the United States, Sun said.

Do you like this story